Amarin--2019's Biggest Buyout Target for Big Pharma
Amarin (AMRN US), a US-listed biotech firm, presented the full results of its "Reduce-It" (RI) clinical trial at a conference for the American...
4.7k Views
Biosimilar Battlefield Update: It's Getting Uglier
A confluence of negative news is causing sharp declines (or trading suspensions) in the share prices of Samsung Biologics Co., (207940...
686 Views
A Conversation with Biogen
Biogen Inc (BIIB US) is Samsung Biologics Co., Ltd (207940 KS) 's minority (5.4%) partner in the Samsung Bioepis JV that manufactures and sells...
334 Views
Will Actinogen Ace Alzheimer's?
Alzheimer’s disease is an incurable neurodegenerative disorder that robs the affected individuals of memory, self-care and quality of life,...
213 Views
Is Merck Paying Peanuts to Viralytics for Full Access to Its Oncolytic Immunotherapy Drug Candidate?
The Merck DealThe competition between the leading checkpoint inhibitor cancer drugs Opdivo/Yervoy (Bristol Myers Squibb Co (BMY US) ) and Keytruda...
254 Views